Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Wyeth meets Street EPS

WYE reported second quarter EPS of $0.45, which is in line with the Street estimate

Read the full 153 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE